Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 17, Issue 8, pp. 1670-1682
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 8, 2018
- Revision received April 16, 2018
- Accepted May 30, 2018
- Published first June 11, 2018.
Article Versions
- Previous version (June 11, 2018 - 05:35).
- Previous version (July 13, 2018 - 06:41).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Yann Wallez1,*,
- Charles R. Dunlop1,
- Timothy Isaac Johnson1,
- Siang-Boon Koh1,2,3,
- Chiara Fornari4,
- James W.T. Yates5,
- Sandra Bernaldo de Quirós Fernández1,
- Alan Lau5,
- Frances M. Richards1,*, and
- Duncan I. Jodrell1
- 1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
- 2Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
- 3Harvard Medical School, Boston, Massachusetts.
- 4Safety and ADME Translational Sciences Department, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
- 5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
- ↵*Corresponding Authors:
Yann Wallez, University of Cambridge, Cambridge CB2 0RE, United Kingdom. Phone: 01223-769642; E-mail: Yann.Wallez{at}cruk.cam.ac.uk; and Frances M. Richards, Fran.Richards{at}cruk.cam.ac.uk
August 2018
Volume 17, Issue 8
Volume 17, Issue 8
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Jump to section
Advertisement